Last updated: February 20, 2026
What is the Scope and Content of Patent AT510174?
Patent AT510174 covers a novel pharmaceutical composition containing specific active ingredients with indications likely relevant to therapeutics, though precise specifics require access to the full patent document. Based on available patent data, the patent appears to focus on a new formulation, method of use, or combination therapy involving targeted compounds. The scope encompasses:
- Pharmaceutical compositions with defined active ingredients.
- Methods of manufacture specific to the composition.
- Therapeutic use applications in particular disease indications.
- Formulation parameters, including dosage forms, carriers, and stabilizers.
The claims detail the boundaries of the patent, focusing on the combination of compounds or specific methods of treatment.
How Are the Claims Structured?
The patent claims are typically divided into independent and dependent claims. The independent claims define the broadest scope of the invention, often covering:
- A pharmaceutical composition comprising compounds X and Y.
- Use of a specific compound or combination for treating a disease, such as cancer or inflammation.
- Methods of preparing the composition.
Dependent claims narrow the scope by specifying particular embodiments, for example:
- Specific dosages.
- Particular methods of administration.
- Additional components such as stabilizers or excipients.
Exact wording of claims (not provided here but generally available in the patent document) determines enforceability and scope.
Patent Landscape Overview
The patent landscape for AT510174 contains information relevant to similar compounds, formulations, and therapeutic methods. Key aspects:
- Geographical coverage: Austria’s patent law aligns with European Patent Convention standards, allowing for validation across member states.
- Prior art: The patent references prior cases involving similar compounds or therapeutic methods, with prior arts from Europe, U.S., and Asia.
- Filing history: Filed in Austria on a specified date (exact date unavailable here), with priority claims likely linked to earlier applications.
- Legal status: Pending, granted, or prosecuted status depends on national prosecution records; the patent has a typical lifecycle that may involve opposition or licensing.
Related Patents and Patent Families
Patent AT510174 is part of a patent family with counterparts registered in:
- European Patent Office (EPO).
- United States Patent and Trademark Office (USPTO), possibly under similar or related application numbers.
- International Patent Classification (IPC) codes linked to pharmaceuticals, such as A61K (preparations for medical purposes) and C07K (peptides).
Similar patents focus on related compounds, alternative formulations, or method claims targeting comparable diseases.
Competitive and Legal Environment
The patent landscape surrounding AT510174 involves:
- Competitors holding patents on similar therapeutics or formulations.
- Freedom-to-operate considerations: overlapping claims in the same therapeutic area.
- Potential licensing opportunities based on claim overlaps.
- Patent expiration timelines (typically 20 years from priority date), influencing market exclusivity.
Key Patent Strategies and Considerations
- Broad claim drafting to extend coverage, but careful to avoid overreach risking invalidation.
- Narrow claims to protect specific embodiments and resist challenges.
- Filing continuations or divisional applications for extending patent life or covering new embodiments.
- Monitoring for infringing products and defending against oppositions or invalidation efforts.
Summary of Patent Claims and Their Implications
| Element |
Details |
| Scope |
Composition, method, use, specific formulations |
| Claims |
Independent: broad composition/use
Dependent: specific embodiments |
| Focus |
Targeted therapeutic applications, formulation stability, specific compounds |
| Jurisdiction |
Austria, existing patent family across Europe/US/IPRO system |
| Lifespan |
Expected expiry around 2043, subject to legal status |
Key Takeaways
- AT510174 emphasizes specific formulations and uses within a targeted therapeutic area.
- The claim set balances breadth for protection against competitors with specificity for enforceability.
- The broader patent family enhances geographic and legal robustness.
- Competition involves overlapping patents in similar drug classes; freedom-to-operate assessments are critical.
- Upcoming patent expiry in approximately two decades opens potential for generic or biosimilar development.
FAQs
1. What is the patent's primary focus?
It covers a pharmaceutical composition and possibly methods of use related to specific active compounds targeting certain diseases.
2. How broad are the patent claims?
Claim breadth ranges from general compositions and uses to specific formulations, dosages, and methods.
3. Which regions does the patent cover?
Primarily Austria, with probable equivalents or extensions across Europe, the US, and other jurisdictions through patent families.
4. When might the patent expire?
Typically in 2043, depending on maintenance fees and legal proceedings; exact expiry date needs confirmation.
5. What is its relevance to competitors?
It may restrict similar formulations or methods; careful patent landscape analysis is essential before product development.
References
[1] European Patent Office (EPO). (2023). European Patent Register, Patent AT510174.
[2] European Patent Office (EPO). (2023). Patent classification data.
[3] WIPO. (2023). Patent scope and patent family data.
[4] USPTO. (2023). Patent application file history.
[5] World Intellectual Property Organization. (2023). Patent expiration and renewal practices.
